Clinical Trial

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-05.
Status change: Not Yet Recruiting → Recruiting 2024-08-20
Trial Details
NCT Number NCT06404281
Lead Sponsor Changzhou No.2 People's Hospital
Conditions Advanced Solid Tumor
Enrollment 9 participants
Start Date 2024-08-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-22